Fact Meets Function

This prospective, randomized, controlled study evaluated ipamorelin, a ghrelin mimetic, as a treatment for postoperative ileus in patients undergoing bowel resection. The research assessed whether ipamorelin could improve recovery of bowel function following surgery in this patient population. This evidence comes from a human clinical trial.

This human clinical study examined whether pulsatile growth hormone secretion patterns persist when using CJC-1295, a long-acting growth hormone-releasing hormone analog, administered as continuous stimulation. The researchers found that pulsatile GH secretion was maintained despite the continuous nature of CJC-1295 stimulation, demonstrating that the body’s natural rhythmic GH release pattern is preserved with this compound. This evidence comes from a human clinical trial design.

This human clinical study examined CJC-1295, a long-acting GH-releasing hormone analog, and found that it stimulated prolonged secretion of growth hormone and insulin-like growth factor I in healthy adult subjects. The extended duration of hormone elevation distinguishes this compound from shorter-acting GH-releasing hormone preparations. This evidence comes from direct human clinical investigation.

This human clinical study developed a pharmacokinetic-pharmacodynamic model to characterize how ipamorelin, a growth hormone-releasing peptide, is absorbed, distributed, and produces effects in the body following administration to healthy volunteers. The modeling approach integrated drug concentration measurements with observed growth hormone responses to predict the relationship between ipamorelin dose and biological effect. This research provides quantitative data on ipamorelin’s time-concentration profile and growth hormone stimulation patterns in humans (human clinical evidence level).